Intellia Therapeutics and San Raffaele University and Research Hospital to Combine CRISPR/Cas9 Genome Editing … – GlobeNewswire (press release)
|
Intellia Therapeutics and San Raffaele University and Research Hospital to Combine CRISPR/Cas9 Genome Editing …
GlobeNewswire (press release) CAMBRIDGE, Mass., and MILAN, Italy, June 06, 2017 (GLOBE NEWSWIRE) — Intellia Therapeutics (NASDAQ:NTLA), a leading genome editing company, and San Raffaele University and Research Hospital, a leading scientific institution, have entered into a … Intellia Therapeutics Inc (NTLA) Rating Reiterated by Wedbush |
